INNATE IMMUNE SUPPRESSION ENABLES REPEATED DELIVERY OF LONG RNA MOLECULES

• US 20100273220A1
• Filed: 04/22/2009
• Published: 10/28/2010
• Est. Priority Date: 04/22/2009
• Status: Abandoned Application

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: YANIK, MEHMET FATIH, ANGEL, MATTHEW
• Application Number:
  US12/428,378
• Publication Number:
  US 20100273220A1
• Time in Patent Office: Days
• US Class Current: 435/91.210
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 15/67 General methods for enhancing the expression
• CPC Class Codes: C12N 2310/14 interfering N.A.

Abstract

The present invention relates in part to methods for suppressing the innate immune response of a cell to transfection with an exogenous nucleic acid, to methods for increasing expression of a protein encoded by an exogenous nucleic acid by repeated delivery of the exogenous nucleic acid to a cell, and to methods of changing the phenotype of a cell by differentiating, transdifferentiating or dedifferentiating cells by repeatedly delivering one or more nucleic acids that encode defined proteins. A method is provided for extended transient transfection by repeated delivery of an in vitro-transcribed RNA (“ivT-RNA”) to a cell to achieve a high and sustained level of expression of a protein encoded by an ivT-RNA transcripts.

Claims

1. A method for suppressing the innate immune response of a cell to transfection with a nucleic acid by introducing to the cell an effective amount of an agent that reduces the expression of one or more proteins in the innate immune response pathway selected from the group consisting of TP53, TLR3, TLR7, RARRES3, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21, IFNK, IFNB1, IL6, TICAM1, TICAM2, MAVS, STAT1, STAT2, EIF2AK2, IRF3, TBK1, CDKN1A, CDKN2A, RNASEL, IFNAR1, IFNAR2, OAS1, OAS2, OAS3, OASL, RB1, ISG15, ISG20, IFIT1, IFIT2, IFIT3, and IFIT5, or to a biologically-active fragment, analog or variant thereof.

2. The method of claim 1, wherein the agent is siRNA, one or more antisense oligonucleotides or any combination thereof.

3. The method of claim 2, wherein the cell is an animal cell and the siRNA or antisense oligonucleotides are specifically hybridizable to an mRNA encoding human TP53, TLR3, TLR7, RARRES3, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21, IFNK, IFNB1, IL6, TICAM1, TICAM2, MAVS, STAT1, STAT2, EIF2AK2, IRF3, TBK1, CDKN1A, CDKN2A, RNASEL, IFNAR1, IFNAR2, OAS1, OAS2, OAS3, OASL, RB1, ISG15, ISG20, IFIT1, IFIT2, IFIT3, and IFIT5, or to a DNA or RNA molecule encoding any of these proteins.

4. The method of claim 1, further comprising contacting the cell with an antibody that selectively binds to a protein in the innate immune response pathway or biologically-active fragment, variant or analog thereof, thereby reducing its biological activity.

5. The method of claim 1, further comprising contacting the cell with a protein or small molecule that reduces the biological activity of a protein in the innate immune response pathway or biologically-active fragment thereof.

6. The method of claim 2, wherein introducing the siRNA or antisense oligonucleotides is accomplished via electroporation, lipid-mediated transfection, ballistic transfection, magnetofection, peptide-mediated transfection, microinjection, or a combination thereof.

34. A cell produced by the method of claim 1.

52. The method of claim 5, wherein the protein is B18R.

7. A method for transfecting a cell with a nucleic acid molecule, which comprises

a. suppressing the innate immune response of the cell, and

b. introducing the nucleic acid into the cell.

8. The method of claim 7, wherein the nucleic acid molecule encodes a protein or biological fragment thereof or an RNA molecule and introducing the nucleic acid is by transfection.

9. The method of claim 7, wherein the nucleic acid is a member selected from the group comprising a single-stranded DNA or RNA molecule, a double-stranded DNA or RNA molecule, or a single- or double-stranded DNA/RNA chimera.

10. The method of claim 9, wherein the single-stranded RNA molecule is in vitro-transcribed RNA encoding a protein of interest.

11. The method of claim 7, wherein steps a and b are simultaneous.

12. The method of claim 7, wherein step a is repeated two or more times.

13. The method of claim 7, wherein step b is repeated two or more times.

14. The method of claim 7, wherein step a is performed up to about 24-72 hours before step b.

15. The method of claim 7, wherein step a comprises introducing to the cell an effective amount of an agent that reduces the expression of one or more proteins in the innate immune response pathway selected from the group consisting of TP53, TLR3, TLR7, RARRES3, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21, IFNK, IFNB1, IL6, TICAM1, TICAM2, MAVS, STAT1, STAT2, EIF2AK2, IRF3, TBK1, CDKN1A, CDKN2A, RNASEL, IFNAR1, IFNAR2, OAS1, OAS2, OAS3, OASL, RB1, ISG15, ISG20, IFIT1, IFIT2, IFIT3, and IFIT5 or a biologically-active fragment, variant or analog thereof.

16. The method of claim 15, wherein the agent is siRNA, one or more antisense oligonucleotides or any combination thereof that area introduced by transfection.

17. The method of claim 16, wherein the cell is an animal cell and the siRNA or one or more antisense oligonucleotides are specifically hybridizable to an mRNA encoding human TP53, TLR3, TLR7, RARRES3, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21, IFNK, IFNB1, IL6, TICAM1, TICAM2, MAVS, STAT1, STAT2, EIF2AK2, IRF3, TBK1, CDKN1A, CDKN2A, RNASEL, IFNAR1, IFNAR2, OAS1, OAS2, OAS3, OASL, RB1, ISG15, ISG20, IFIT1, IFIT2, IFIT3, and IFIT5 or a biologically-active fragment, variant or analog thereof, or to a DNA or RNA molecule encoding any of these proteins.

18. The method of claim 15, further comprising contacting the cell with an antibody that selectively binds to a protein in the innate immune response pathway or to a biologically-active fragment, variant or analog thereof, thereby reducing its biological activity.

19. The method of claim 15, further comprising contacting the cell with a protein or small molecule that reduces the biological activity of a protein in the innate immune response pathway or biologically-active fragment thereof.

20. The method of claim 7, wherein the cell is an animal cell.

21. The method of claim 20, wherein the animal is a human.

22. The method of claim 7, wherein steps a and b are accomplished using electroporation, lipid-mediated transfection, ballistic transfection, magnetofection, peptide-mediated transfection, microinjection or a combination thereof.

23. The method of claim 8, wherein the nucleic acid encodes a protein selected from the group consisting of OCT4, the mRNA of which comprises SEQ ID NO:

1;

SOX2, the mRNA of which comprises SEQ ID NO;

2;

KLF4, the mRNA of which comprises SEQ ID NO;

3;

MYC, the mRNA of which comprises SEQ ID NO;

4;

NANOG, the mRNA of which comprises SEQ ID NO;

5;

LIN28, the mRNA of which comprises SEQ ID NO;

6;

MYOD1, the mRNA of which comprises SEQ ID NO;

7;

Ascl1. the mRNA of which comprises SEQ ID NO;

8;

PU.1, the mRNA of which comprises SEQ ID NO;

9;

C/EBPα

, the mRNA of which comprises SEQ ID NO;

10;

C/EBPβ

, the mRNA of which comprises SEQ ID NO;

11;

Ngn3, the mRNA of which comprises SEQ ID NO;

12;

Pdx1, the mRNA of which comprises SEQ ID NO;

13;

Mafa, the mRNA of which comprises SEQ ID NO;

14; and

Esrrb, the mRNA of which comprises SEQ ID NO;

15, or a biologically-active fragment, analog or variant thereof.

24. The method of claim 8, wherein expression of the encoded protein or RNA molecule causes a desired phenotypic change in the cell.

25. The method of claim 24, wherein the cell is an animal cell and the desired phenotypic change is cell differentiation, transdifferentiation, or dedifferentiation.

26. The method of claim 25, wherein the animal is a mammal, the cell is an adult hippocampal stem cell, the encoded protein is Ascl1 and the phenotypic change is differentiation of the cell to an oligodendrocyte.

27. The method of claim 25, wherein the animal is a mammal, the cell is a neural stem cell, the cell is transfected with a plurality of different in vitro transcribed-RNAs each encoding Oct4, Klf4 or c-Myc protein, and the phenotypic change is dedifferentiation of the neural stem cell to a pluripotent stem cell.

28. The method of claim 25, wherein the animal is a mammal, the cell is a non-insulin-producing pancreatic exocrine cell, the cell is transfected with a plurality of different in vitro-transcribed RNAs each encoding Ngn3, Pdx1, or Mafa protein, and the phenotypic change is transdifferentiation of the non-insulin-producing pancreatic exocrine cell to an insulin-producing beta islet cell.

29. The method of claim 25, wherein the animal is a mammal, the cell is a fibroblast, the cell is transfected with a plurality of different in vitro-transcribed RNAs each encoding Oct4, Sox2, Klf4, and c-Myc protein, and the phenotypic change is dedifferentiation of the fibroblast to a pluripotent stem cell.

30. The method of claim 25, wherein the animal is a mammal, the cell is a member selected from the group comprising a fibroblast, a chondroblast, a smooth muscle cell, and a retinal pigmented epithelial cell, the encoded protein is MyoD, and the desired phenotypic change is transdifferentiation of the cell to a myoblast.

31. The method of claim 25, wherein the animal is a mammal, the cell is a fibroblast, the cell is transfected with a plurality of different in vitro-transcribed RNAs each encoding PU.1 or C/EBPα

/β

, and the desired phenotypic change is transdifferentiation of the fibroblast to a macrophage.

35. A cell produced by the method of claim 7.

32. A composition comprising a plurality of different siRNAs, one or more antisense oligonucleotides, or combinations thereof that specifically hybridize to mRNA or DNA molecules encoding two or more proteins in the innate immune response pathway selected from the group comprising TP53, TLR3, TLR7, RARRES3, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21, IFNK, IFNB1, IL6, TICAM1, TICAM2, MAVS, STAT1, STAT2, EIF2AK2, IRF3, TBK1, CDKN1A, CDKN2A, RNASEL, IFNAR1, IFNAR2, OAS1, OAS2, OAS3, OASL, RB1, ISG15, ISG20, IFIT1, IFIT2, IFIT3, IFIT5 or biologically-active fragments, variants or analogs thereof, or to a DNA or RNA molecule encoding any of the enumerated proteins, thereby reducing expression of the two or more proteins.

33. The composition of claim 32, comprising a mixture of siRNAs that specifically hybridize to mRNA or DNA molecules encoding TP53, STAT2, and EIF2AK2, or a mixture of siRNAs that specifically hybridize to mRNA or DNA molecules encoding TP53, STAT2, EIF2AK2, and IFNB1.

36. A DNA template comprising, a transcription promoter operably linked to a construct that produces an in vitro-transcribed RNA comprising,

(i) a stable 5′

UTR, and

(ii) a strong Kozak consensus sequence linked to a protein coding sequence (CDS).

37. The template of claim 36, wherein the construct has a first restriction site which joins the stable 5′

UTR to the strong Kozak consensus sequence.

38. The template of claim 37, wherein the first restriction site is an NheI site.

39. The template of claim 36, further comprising (iii) a stable 3′

UTR.

40. The template of claim 39, wherein the stable 3′

UTR and the stable 5′

UTR are the beta globin UTR or the alpha globin UTR.

41. The template of claim 39, wherein the construct has a second restriction site which joins the CDS to the stable 3′

UTR.

42. The template of claim 41, wherein the second restriction site is an AgeI site

43. The template of claim 36, further comprising an internal ribosome entry site.

44. The template of claim 36, wherein the promoter is a member selected from the group comprising T7, T3, and SP6.

45. An in vitro-transcribed RNA transcript encoding a protein of interest, comprising in operable combination,

(i) a stable 5′

UTR, and

(ii) a strong Kozak sequence linked to a protein coding sequence (CDS).

46. The transcript of claim 45, further comprising (iii) a stable 3′

UTR.

47. The transcript of claim 46, wherein the stable 3′

UTR and the stable 5′

UTR are the beta globin UTRs or the alpha globin UTRs or any combination thereof.

48. The transcript of claim 45, further comprising one or more of the following elements:

a poly(A) tail at the 3′

end of the transcript, a 7-methylguanosine cap at the 5′

end of the transcript, and an internal ribosome entry site.

49. The transcript of claim 45, wherein the protein of interest is selected from the group consisting of OCT4 the mRNA of which comprises SEQ ID NO:

1, SOX2 the mRNA of which comprises SEQ ID NO;

2, KLF4 the mRNA of which comprises SEQ ID NO;

3, MYC the mRNA of which comprises SEQ ID NO;

4, NANOG the mRNA of which comprises SEQ ID NO;

5, LIN28 the mRNA of which comprises SEQ ID NO;

6, MYOD1 the mRNA of which comprises SEQ ID NO;

7, Ascl1 the mRNA of which comprises SEQ ID NO;

8, PU.1 the mRNA of which comprises SEQ ID NO;

9, C/EBPα

the mRNA of which comprises SEQ ID NO;

10, C/EBPβ

the mRNA of which comprises SEQ ID NO;

11, Ngn3 the mRNA of which comprises SEQ ID NO;

12, Pdx1 the mRNA of which comprises SEQ ID NO;

13, Mafa the mRNA of which comprises SEQ ID NO;

14, and Esrrb the mRNA of which comprises SEQ ID NO;

15, or a biologically-active fragment, analog or variant thereof.

50. A kit comprising a DNA template having a strong transcription promoter operably linked to a construct that produces an in vitro-transcribed RNA comprising,

(i) a stable 5′

UTR, and

(ii) a first restriction site capable of joining the 5′

UTR to a Kozak consensus sequence.

51. The kit of claim 50, further comprising one or more of the following:

a polymerase that recognizes and binds to the promoter, a buffer suitable for conducting an in vitro-transcription reaction, a mixture of nucleotide triphosphates (NTPs), the restriction enzymes that recognize the first and the second restriction sites, a DNAse enzyme solution for degrading the used template once the in vitro-transcription reaction is complete, a capping enzyme for producing the 5′

m7G cap, a 2-O-methyltransferase enzyme for adding a methyl group to the second nucleotide, a solution of GTP, a solution of S-adenosyl methionine (SAM), a poly(A) polymerase enzyme (for example E. coli poly(A) polymerase), a solution of ATP, and a buffer for the poly(A)-tailing reaction. The kit may further include a DNA template to be used as a positive control.